期刊文献+

环孢素、硝苯地平等5种肾移植受者常用药物对人体红细胞硫嘌呤甲基转移酶活性的影响 被引量:2

Effects of five drugs including ciclosporin and nifedipine which were usually used in patients with kidney transplantation on erythrocyte thiopurine methyltransferase activity
下载PDF
导出
摘要 目的:研究肾移植受者中常与硫唑嘌呤(AZA)同时服用的药物如环孢素、泼尼松的活性代谢物氢化可的松、硝苯地平、卡托普利以及别嘌呤醇对硫嘌呤甲基转移酶(TPMT)活性的影响。方法:应用高效液相色谱法(HPLC)测定健康受试者红细胞TPMT活性,其中中等活性和正常活性受试者各8例,计算药物各浓度对应的平均TPMT活性抑制率及有抑制作用药物的平均IC_(50)值。结果:环孢素、氢化可的松、卡托普利以及别嘌呤醇对TPMT活性抑制作用较弱。硝苯地平能明显抑制TPMT的活性,中等活性组的平均IC_(50)值为(24±17)μg/mL,正常活性组的平均,IC_(50)值为(12±10)μg/mL。结论:硝苯地平能明显抑制TPMT活性,当硝笨地平与嘌呤类药物同时服用时,应警惕可能发生不良相互作用。 AIM: To investigate the effects of five drugs which were usually used simultaneously with azathioprine (AZA) in patients with kidney transplantation: ciclosporin, hydrocortisone, nifedipine, captopril and allopurinol on erythrocyte thiopurine methyltransferase (TPMT) activity. METHODS: The erythrocyte TPMT activity of healthy volunteers was measured by high-performance liquid chromatography (HPLC). Sixteen volunteers were chosen, in which 8 cases with intermediate TPMT activity and others with normal TPMT activity. The mean inhibition ratio of each drug concentration and the mean IC50 values of the inhibitors were determined. RESULTS: Ciclosporin, hydrocortisone, captopril and allopurinol had nearly no impacts on TPMT activity. Nifedipine highly inhibited TPMT activity in vitro, the mean IC50 value in intermediate TPMT activity group was (24 ± 17) μg/mL and in normal TPMT activity group was ( 12 ± 10) μg/mL. CONCLUSION: The co-administration of nifedipine and thiopurines may lead to drug interactions.
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第12期1411-1414,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 全军科学技术研究"十一五"计划课题资助(06MA131)
关键词 硫嘌呤甲基转移酶 硫唑嘌呤 环孢素 氢化可的松 硝苯地平 卡托普利 别嘌呤醇 thiopurine methyltransferase azathioprine ciclosporin hydrocortisone nifedipine captopril allopurinol
  • 相关文献

参考文献13

  • 1Lennard L. TPMT in the treatment of Crohn's disease with azathioprine[J]. Gut, 2002;51 : 143 - 146.
  • 2Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysisof thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants[J]. Pharmacogenetics, 2004; 14:407-417.
  • 3Lysaa RA, Giverhaug T, Wold HL, et al. Inhibition of human thiopurine S-methyltransferase by furosemide, bendrotlumetheiazide and trichlormethiazide[J]. Eur J Chin Pharmacol, 1996; 49:393 - 396.
  • 4辛华雯,Christine Fischer,Matthias Schwab,Ulrich Klotz.速尿、苯氧比酸、硫唑嘌呤对慢性炎症性肠病患者红细胞TPMT活性的影响[J].中国临床药理学与治疗学,2005,10(6):655-658. 被引量:3
  • 5Egan LJ. Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid[ J]. Clin Gastroenterol Hepatol, 2004;2:725-730.
  • 6Xin H, Fischer C, Schwab M, et al. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2005 ; 21 : 1105 - 1109.
  • 7熊晖,熊磊,苏丹,辛华雯,吴笑春,李罄,李高.HPLC法检测人红细胞中巯嘌呤甲基转移酶的活性[J].中国药师,2007,10(8):738-740. 被引量:4
  • 8Jacqz-Aigrain E, Bessa E, Medard Y, et al. Thiopurine methyltransferase activity in a French population: h.p. l. c. assay conditions and effectsof drugs and inhibitors[J]. Br J Clin Pharmaeol, 1994;38:1 - 8.
  • 9Holme SA, Duley JA, Sanderson J, et al. Erythrecyte thiopurine methyltransferase assessment prior to Azathiopurine use in the UK[J]. QJM, 21302;95:439-444.
  • 10Cara C J, Pena AS, Sans M, et al. Reviewing the mechanism of actionof thiopurine drugs: Towards a new paradigm in clinical practice[J]. Med Sci Monit, 2004; 10:247 - 254.

二级参考文献31

  • 1马晓莉,朱平,胡亚美,吴敏媛.反相高效液相色谱法测定红细胞中巯嘌呤甲基转移酶的活性[J].药物分析杂志,2004,24(5):468-470. 被引量:3
  • 2张波,徐小薇,付强,李大魁.人红细胞中巯嘌呤甲基转移酶活性的HPLC测定法[J].中国药学杂志,2004,39(12):941-943. 被引量:7
  • 3葛健,夏瑞祥,曾庆曙,金涌,过林,陈纭.高效液相色谱法测定急性淋巴细胞白血病患者巯嘌呤甲基转移酶活性[J].中国医院药学杂志,2006,26(5):520-522. 被引量:5
  • 4Berg KJ,Walstad RA, Bergh K. The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency[J]. Br J Clin Pharmacol, 1983; 15:347-53
  • 5Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia[J]. Lancet, 1990; 336:225-9
  • 6Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients[J]. Transplantation, 1992; 53:1051-6
  • 7Capdeville R, Mousson B, Bax G, Bertrand Y, Philippe N. Interactions between 6-mercaptopurine therapy and thiopurine methyltransferase (TPMT) activity[J]. Eur J Clin Pharmacol, 1994; 46:385-6
  • 8Renas M, Duley JA, Ansari A, Schobowale-Bakre EA, Fairbanks L, Soon SY, et al. Genetic determinants of the pre-and post-azathioprine therapy thiopurine methyltransferase activity phenotype[J]. Nucleos Nucleot Nucl Acids, 2004; 23:1403-5
  • 9Lin SN, Jessup K, Floyd M, Wang TP, van Buren CT, Caprioli RM, et al. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients[J]. Transplantation, 1980; 29:290-4
  • 10Schwab M,Klotz U. Pharmacokinetic consideration in the treatment of inflammatory bowel disease [J]. Clin Pharmacokinet, 2001;40:723-51

共引文献4

同被引文献21

  • 1辛华雯,Christine Fischer,Matthias Schwab,Ulrich Klotz.速尿、苯氧比酸、硫唑嘌呤对慢性炎症性肠病患者红细胞TPMT活性的影响[J].中国临床药理学与治疗学,2005,10(6):655-658. 被引量:3
  • 2Vanderheiden B S. Purification and properties of human erythrocyte inosine triphosphate pyrophosphohydrolase [ J ]. J Cell Physiol, 1979,98(1) :41 -7.
  • 3Shipkova M, Lorenz K, Oellerich M, et al. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase ( ITPA ) activity by HPLC and correlation of ITPA genotype-phenotype in a caucasian population[J]. Clin Chem,2006,52(2):140-7.
  • 4Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population [J]. Mol Genet Metab ,2005 ,85( 4 ) :271 -9.
  • 5Lennard L. TPMT in the treatment of Crohn's disease with azathioprine [ J ]. Gut,2002,51 (2) : 143 - 6.
  • 6Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy andad- verse drug reactions in patients within flammatory bowel disease: impact of thiopurine S-methyhransferase polymorphism [ J ]. Pharmacgenetics, 2002,12 (6) :429 - 36.
  • 7Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in in Xammatory bowel disease [ J ]. Aliment Pharmacol Ther,2002,16 (10) : 1743 - 50.
  • 8Kirschner B S. Salty of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease [ J ]. Gastroenterology,1998,115(4) :813 -21.
  • 9Marinaki A M, Ansari A, Duley J A, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPA) [ J ]. Pharmacogenetics ,2004,14( 3 ) : 181 - 7.
  • 10Marinaki A M, Ansari A, Duley J A, et al. Mutation in the ITPA gene predicts intolerance to azathioprine [ J ]. Nucleosides Nucleotides Nucleic Acids ,2004,23(8-9) :1393 -7.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部